Home | News | Find a Doctor | Ask a Question | Free

Aderans Research Treats One-Hundredth Subject in Clinical Study


#1

Atlanta, GA (PRWEB) February 28, 2010 – Aderans Research Institute Inc. (ARI) recently achieved a significant milestone in its Phase 2 clinical study of cell-based hair regeneration, treating the trial’s 100th subject. With clinical sites expected to double in the coming months, the study will likely add dozens of additional subjects to its enrollment.
“The breadth of this phase of our trial is tremendous,” said Kurt Stenn, MD, Vice President and Chief Scientific Officer. “We have significantly more participants than our Phase 1 study. The improved quantity of our study group allows us to assess our cell-products and accelerate our efforts to truly understand the impact of cell regeneration on pattern hair loss.”
Phase 2 of the study has thus far been conducted in eight cities: Atlanta, Boston, Chicago, New York, Paramus, Raleigh, Houston, and Washington DC. The study will ultimately comprise at least 16 U.S. metropolitan areas, with numerous new cities expected to be added in the coming months.
The second phase of the trial is testing a variety of treatment regimens designed to realize a unique autologous cell engineering solution to hair regeneration. During the treatment, a small section of hair-bearing tissue is removed, cells are extracted and cultivated in a controlled laboratory setting, and then reintroduced to the scalp, where they are expected to elicit new hair growth.
“This is leading edge research in our industry,” said Vern Liebmann, Vice President, Operations. “We’ve been able to conduct this study largely due to the generous financial backing of Aderans Co. LTD of Japan, and we’re collectively very excited to see the results beginning later this year.”
Phase 1 of the clinical study was conducted exclusively in the UK. More than 30% of participants showed a viable response to ARI’s cellular regeneration techniques.
About Aderans Research
Aderans Research is a pioneer in the research and development of safe, effective cell engineered products for hair regeneration. With offices in Atlanta and Philadelphia, Aderans Research Institute is a subsidiary of Aderans Company, Ltd, the world’s largest wig manufacturer, and an affiliate of Bosley, a global leader in medical hair restoration.


#2

» Atlanta, GA (PRWEB) February 28, 2010 – Aderans Research Institute Inc.
» (ARI) recently achieved a significant milestone in its Phase 2 clinical
» study of cell-based hair regeneration, treating the trial’s 100th subject.
» With clinical sites expected to double in the coming months, the study will
» likely add dozens of additional subjects to its enrollment.
» “The breadth of this phase of our trial is tremendous,” said Kurt Stenn,
» MD, Vice President and Chief Scientific Officer. “We have significantly
» more participants than our Phase 1 study. The improved quantity of our
» study group allows us to assess our cell-products and accelerate our
» efforts to truly understand the impact of cell regeneration on pattern hair
» loss.”
» Phase 2 of the study has thus far been conducted in eight cities: Atlanta,
» Boston, Chicago, New York, Paramus, Raleigh, Houston, and Washington DC.
» The study will ultimately comprise at least 16 U.S. metropolitan areas,
» with numerous new cities expected to be added in the coming months.
» The second phase of the trial is testing a variety of treatment regimens
» designed to realize a unique autologous cell engineering solution to hair
» regeneration. During the treatment, a small section of hair-bearing tissue
» is removed, cells are extracted and cultivated in a controlled laboratory
» setting, and then reintroduced to the scalp, where they are expected to
» elicit new hair growth.
» “This is leading edge research in our industry,” said Vern Liebmann, Vice
» President, Operations. “We’ve been able to conduct this study largely due
» to the generous financial backing of Aderans Co. LTD of Japan, and we’re
» collectively very excited to see the results beginning later this year.”
» Phase 1 of the clinical study was conducted exclusively in the UK. More
» than 30% of participants showed a viable response to ARI’s cellular
» regeneration techniques.

» About Aderans Research
» Aderans Research is a pioneer in the research and development of safe,
» effective cell engineered products for hair regeneration. With offices in
» Atlanta and Philadelphia, Aderans Research Institute is a subsidiary of
» Aderans Company, Ltd, the world’s largest wig manufacturer, and an
» affiliate of Bosley, a global leader in medical hair restoration.
»
» http://www.prweb.com/releases/hair/regeneration/prweb3661844.htm

What?? Only 30% showed a viable response? “Viable response” must mean more than any response, or else I really can’t see them proceeding with phase II trials.


#3

Same comment.
everything in the article looks fantastic, everything as scheduled, more than 100 trialists, and japanese money flowing plentiful.
But we reach the end of the article, and it isn’t pretty.
I think it is clear that Phase I didn’t work well, but they are testing many different formulas in the Phase II trial.
Lets cross our (remaining) follicles.

In any case, there is no doubt that ARI is engaging in a generous and sincere attempt to find a solution. Not like ICX-TRC, whose trials were a joke, more propaganda than anything.

quote:

The second phase of the trial is testing a variety of treatment regimens designed to realize a unique autologous cell engineering solution to hair regeneration.
<<


#4

Great News! Now thats the way to do a trial…loads of trialists…several different treatments…I hope the crack this disease in these trails!


#5

» Same comment.
» everything in the article looks fantastic, everything as scheduled, more
» than 100 trialists, and japanese money flowing plentiful.
» But we reach the end of the article, and it isn’t pretty.
» I think it is clear that Phase I didn’t work well, but they are testing
» many different formulas in the Phase II trial.
» Lets cross our (remaining) follicles.
»
» In any case, there is no doubt that ARI is engaging in a generous and
» sincere attempt to find a solution. Not like ICX-TRC, whose trials were a
» joke, more propaganda than anything.

I agree. This is positive news because they are doing a ton of well-thought-out research. If they try a lot of different variations of the procedure, they can begin to optimize their treatment. Maybe they will even find something that merits phase 3 trials.

I really think that if anyone can come up with a viable hm treatment, it is Aderans.


#6

Lets hope so. 30% seems quite low even if it was only in phase 1… :expressionless:


#7

» » Same comment.
» » everything in the article looks fantastic, everything as scheduled,
» more
» » than 100 trialists, and japanese money flowing plentiful.
» » But we reach the end of the article, and it isn’t pretty.
» » I think it is clear that Phase I didn’t work well, but they are testing
» » many different formulas in the Phase II trial.
» » Lets cross our (remaining) follicles.
» »
» » In any case, there is no doubt that ARI is engaging in a generous and
» » sincere attempt to find a solution. Not like ICX-TRC, whose trials were
» a
» » joke, more propaganda than anything.
»
» I agree. This is positive news because they are doing a ton of
» well-thought-out research. If they try a lot of different variations of
» the procedure, they can begin to optimize their treatment. Maybe they will
» even find something that merits phase 3 trials.
»
» I really think that if anyone can come up with a viable hm treatment, it
» is Aderans.

It seems that Aderans is our only hope now.


#8

» Atlanta, GA (PRWEB) February 28, 2010 – Aderans Research Institute Inc.
» (ARI) recently achieved a significant milestone in its Phase 2 clinical
» study of cell-based hair regeneration, treating the trial’s 100th subject.
» With clinical sites expected to double in the coming months, the study will
» likely add dozens of additional subjects to its enrollment.
» “The breadth of this phase of our trial is tremendous,” said Kurt Stenn,
» MD, Vice President and Chief Scientific Officer. “We have significantly
» more participants than our Phase 1 study. The improved quantity of our
» study group allows us to assess our cell-products and accelerate our
» efforts to truly understand the impact of cell regeneration on pattern hair
» loss.”
» Phase 2 of the study has thus far been conducted in eight cities: Atlanta,
» Boston, Chicago, New York, Paramus, Raleigh, Houston, and Washington DC.
» The study will ultimately comprise at least 16 U.S. metropolitan areas,
» with numerous new cities expected to be added in the coming months.
» The second phase of the trial is testing a variety of treatment regimens
» designed to realize a unique autologous cell engineering solution to hair
» regeneration. During the treatment, a small section of hair-bearing tissue
» is removed, cells are extracted and cultivated in a controlled laboratory
» setting, and then reintroduced to the scalp, where they are expected to
» elicit new hair growth.
» “This is leading edge research in our industry,” said Vern Liebmann, Vice
» President, Operations. “We’ve been able to conduct this study largely due
» to the generous financial backing of Aderans Co. LTD of Japan, and we’re
» collectively very excited to see the results beginning later this year.”
» Phase 1 of the clinical study was conducted exclusively in the UK. More
» than 30% of participants showed a viable response to ARI’s cellular
» regeneration techniques.
» About Aderans Research
» Aderans Research is a pioneer in the research and development of safe,
» effective cell engineered products for hair regeneration. With offices in
» Atlanta and Philadelphia, Aderans Research Institute is a subsidiary of
» Aderans Company, Ltd, the world’s largest wig manufacturer, and an
» affiliate of Bosley, a global leader in medical hair restoration.
»
» http://www.prweb.com/releases/hair/regeneration/prweb3661844.htm

They ever say when phase II was scheduled to be completed?


#9

» They ever say when phase II was scheduled to be completed?

read once again:

» “This is leading edge research in our industry,” said Vern Liebmann, Vice
» President, Operations. “We’ve been able to conduct this study largely due
» to the generous financial backing of Aderans Co. LTD of Japan, and we’re
» collectively very excited to see the results beginning later this year.


#10

» What?? Only 30% showed a viable response? “Viable response” must mean more
» than any response, or else I really can’t see them proceeding with phase II
» trials.

I think the 30% figure is referring to Phase I. In Phase I they were only looking whether there were any safety issues. We won’t know whether this is a viable treatment before we know the results of phase II.
I actually think this is the most exciting article I have read for a very long time. Clearly they are on to something here: Trials are expensive (especially if they are as big as this), and they wouldn’t spend all that money if they didn’t think that they were close to finding the cure. This is great news!!!


#11

which the reason of the joy here. aderans did not say nothing, therefore it does not have nothing saying in them. these reports are not different of intercytex, all vacant, nothing really explained. after 10 years of research, them not yet it has nothing, and they will not have in next the 5 years. I believe that if we will have one cure, this cure will be through trichoscience, or histogen, not of aderans.


#12

This is the first time that we have a decent trial. At least they have balls.
And they are not playing propaganda games. It is a sincere trial. Kudos for them, even if they fail.

» which the reason of the joy here. aderans did not say nothing, therefore it
» does not have nothing saying in them. these reports are not different of
» intercytex, all vacant, nothing really explained. after 10 years of
» research, them not yet it has nothing, and they will not have in next the 5
» years. I believe that if we will have one cure, this cure will be through
» trichoscience, or histogen, not of aderans.


#13

This is the first teams that we have decent trial. … TRIAL that already lasts 10 years, without no photo, image, nothing, only that almost annual reports on its (advances). Aderans does not have nothing, and it will not have in the next years, and exactly thus they finance a group of scientists, doctors and directors, among others good they thus for having money, to materem the wages of people as kurt stenn…


#14

» This is the first teams that we have decent trial. … TRIAL that already
» lasts 10 years, without no photo, image, nothing, only that almost annual
» reports on its (advances). Aderans does not have nothing, and it will not
» have in the next years, and exactly thus they finance a group of
» scientists, doctors and directors, among others good they thus for having
» money, to materem the wages of people as kurt stenn…

the fact that they have not released photos really doesnt mean anything. How would they profit by showing YOU photos of their trails? Releasing photo images would only help their competitors. As has been said before… clinical trails are extremely costly, they have obviously managed to convince their investors who have real money at stake to finance them… I’m sure THEY have seen photos. As soon as you have a reasonable amount of money you can introduce yourself to them as a possible investor and maybe then you’ll get to see smoe real trail images… until then you’re just another troll on a hairloss forum with no meaning to them whatsoever.

Another reason why images are not released during on going trails is because trailists are not supposed to be influenced by them… creating or reducing placebo effects by seeing what other patients look like. It’s yet another reason why trail imagery is withheld from the public…

I do consider myself sceptical of news but i agree that this article is one of the most exciting ones i’ve read in a while… really looking forward to seeing the results.


#15

photos are not nothing? images are not nothing? ok, what then valley? information on the progress of aderans in the 10 last years? ok, really, who knows in next the 10 years they in does not show some thing to them where to believe, beyond percentages. they from fear do not show the results in images of the competitors? ok… where you live hairman2? in the moon??? if aderans showed something relamente functional, I myself would be one of its shareholders, that exactly minority, I would invest to each cent mine on its quotas, this if they showed something to me, not made annual reports as intercytex, they say say say, and they do not say nothing.


#16

baldlatino, you are right, photos are very important.
but note that ARI is fully funded, they don’t need to present proof as ICX needed.
for now, I am happy that they are testing 100+ trialists, and, AFAIK, they are not using this trial as a show to advertise Bosley’s HTs.
looks like a honest attempt to find the cure.

» photos are not nothing? images are not nothing? ok, what then valley?
» information on the progress of aderans in the 10 last years? ok, really,
» who knows in next the 10 years they in does not show some thing to them
» where to believe, beyond percentages. they from fear do not show the
» results in images of the competitors? ok… where you live hairman2? in the
» moon??? if aderans showed something relamente functional, I myself would be
» one of its shareholders, that exactly minority, I would invest to each cent
» mine on its quotas, this if they showed something to me, not made annual
» reports as intercytex, they say say say, and they do not say nothing.


#17

the images you’re talking about are only important to satisfy the inquisitiveness of hairloss forum users? Honestly, if i a working procedure in a field with a strong competition. I would try to withhold as much information as possible to the public and only show the neccessities to convince my investors. And i wouldn’t care if people on hairloss forums speculated about the effectiveness of my procedure.

and i never said images are meaningless… i said the fact that we haven’t seen them… does not mean they don’t exist.

it just means that they are not interested in receiving money from tiny investors like you… they have their own funding…

» baldlatino, you are right, photos are very important.
» but note that ARI is fully funded, they don’t need to present proof as ICX
» needed.
» for now, I am happy that they are testing 100+ trialists, and, AFAIK, they
» are not using this trial as a show to advertise Bosley’s HTs.
» looks like a honest attempt to find the cure.
»
»
»
»
» » photos are not nothing? images are not nothing? ok, what then valley?
» » information on the progress of aderans in the 10 last years? ok,
» really,
» » who knows in next the 10 years they in does not show some thing to them
» » where to believe, beyond percentages. they from fear do not show the
» » results in images of the competitors? ok… where you live hairman2? in
» the
» » moon??? if aderans showed something relamente functional, I myself would
» be
» » one of its shareholders, that exactly minority, I would invest to each
» cent
» » mine on its quotas, this if they showed something to me, not made
» annual
» » reports as intercytex, they say say say, and they do not say nothing.


#18

I too, have a pessimistic stance with any company which don’t furnish any proof-of-concept evidence to the public. But then again, one has to look at the dynamics of what they’re trying to do; is it to not expose themselves to the competition and the inherent cost of being cloaky or is it because they don’t have any proof?

Last week, Bloom Energy, reveal themselves to the world of their progress in the fuel cell technology. Not only were they running stealth-like, no big company signs or logos but that they were operating with a cloak, secretive mission as they were building their machines. It was then revealed that they have been building these generators and actually have them installed for years, in a number of companies which evidently have signed non-disclosures as well.

Bloom is evidently marketing themselves to the VCs and not the public investor. This allows them to hold off on talking about their trade secrets until its time when they’re ready.

Hopefully Aderans is following the same model.


#19

I hate to speak of timelines, but are we looking at three years if all goes to plan?


#20

» I hate to speak of timelines, but are we looking at three years if all goes
» to plan?

Till commercialization? Try double that. Phase II will be done “later this year”, then the data has to be analyzed, the decision made to whether or not to go forward, then Phase III begun, completed, and submitted to the FDA. Then it has to be approved, and the protocol and its associated equipment has to be mass-produced and taught.